Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals’ arm launches Axitinib Tablets

16 Nov 2026 Evaluate

Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Pharmaceuticals Inc., USA, (Glenmark) has launched Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA (axitinib) tablets. According to IQVIA sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA Tablets were around $538.4 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Peers
Company Name CMP
Sun Pharma. Inds. 1873.80
Dr. Reddys Labs. 1384.35
Cipla 1387.90
Lupin 1948.20
Zydus Lifesciences 1201.35
View more..